These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11257811)

  • 21. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
    Bianchetti A; Rozzini R; Trabucchi M
    Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
    Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
    No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-Alzheimer drugs: ethical aspects of research and practice].
    Berghmans RL
    Tijdschr Gerontol Geriatr; 2000 Jun; 31(3):100-6. PubMed ID: 10900662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
    Gabelli C
    Curr Med Res Opin; 2003; 19(2):69-82. PubMed ID: 12740150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Gauthier S; Bodick N; Erzigkeit E; Feldman H; Geldmacher DS; Huff J; Mohs R; Orgogozo JM; Rogers S
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():6-7. PubMed ID: 9305507
    [No Abstract]   [Full Text] [Related]  

  • 28. Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Amaducci L; Baldereschi M; Doody R; Chandra V; Gaines AD
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():19-21. PubMed ID: 9305509
    [No Abstract]   [Full Text] [Related]  

  • 29. [New therapies in neurology, but who benefits?].
    Vermeulen M; de Haan RJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1764-6. PubMed ID: 10494326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
    Bullock R; Passmore P; Wilkinson D; Howard R; Jones R
    BMJ; 2000 Feb; 320(7233):511-2. PubMed ID: 10678874
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of repeated measurements with dropouts among Alzheimer's disease patients using summary measures and meta-analysis.
    Talwalker S
    J Biopharm Stat; 1996 Mar; 6(1):49-58. PubMed ID: 8838778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Alzheimer disease: efficacy and tolerance of rivastagmine].
    Hébert M
    Presse Med; 1999 Oct; 28(32):1757-8. PubMed ID: 10566280
    [No Abstract]   [Full Text] [Related]  

  • 33. [Alzheimer's disease].
    Giménez-Roldán S
    Rev Neurol; 1995; 23(119):96-102. PubMed ID: 8548651
    [No Abstract]   [Full Text] [Related]  

  • 34. Power and sample size determination when assessing the clinical relevance of trial results by 'responder analyses'.
    Kieser M; Röhmel J; Friede T
    Stat Med; 2004 Nov; 23(21):3287-305. PubMed ID: 15490433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NICE approves drugs for Alzheimer's disease.
    Kmietowicz Z
    BMJ; 2001 Jan; 322(7280):190. PubMed ID: 11159606
    [No Abstract]   [Full Text] [Related]  

  • 36. Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life.
    Yehuda S; Rabinovtz S; Carasso RL; Mostofsky DI
    Int J Neurosci; 1996 Nov; 87(3-4):141-9. PubMed ID: 9003975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The measuring, meaning and importance of activities of daily living (ADLs) as an outcome.
    Rockwood K
    Int Psychogeriatr; 2007 Jun; 19(3):467-82. PubMed ID: 17359560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment.
    Wimo A; Winblad B; Grafstrom M
    Int J Geriatr Psychiatry; 1999 May; 14(5):338-47. PubMed ID: 10389036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dimebon in Alzheimer's disease: old drug for new indication.
    Burns A; Jacoby R
    Lancet; 2008 Jul; 372(9634):179-80. PubMed ID: 18640436
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical issues of cognitive enhancers in Alzheimer disease.
    Calvani M; Carta A
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S25-31. PubMed ID: 1781971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.